BioArctic and Mesenkia Target Glioblastoma With Antibody
Stockholm, Sweden, August 19, 2026 BioArctic AB and Mesenkia Therapeutics have entered a research collaboration to explore a novel...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Stockholm, Sweden, August 19, 2026 BioArctic AB and Mesenkia Therapeutics have entered a research collaboration to explore a novel...
Ramat Gan, Israel, August 19, 2026 Pulsenmore Ltd. announced the expansion of its home ultrasound activities in Israel following...
RAMAT GAN, Israel — August 17, 2026 Pulsenmore Ltd. has received a $1.27 million grant from the Israel Innovation...
